ASX ANNOUNCEMENT

IMPEDIMED ANNOUNCES BOARD OF DIRECTORS AND EXECUTIVE MANAGEMENT CHANGES

Brisbane, Australia – ImpediMed Limited (ASX: IPD) (“ImpediMed”) announces the resignation of Greg Brown from his Executive Director role on the Board as of 30th September 2013. Greg’s extensive history with ImpediMed is dominated by his role as Managing Director/CEO but also includes investor and consultant roles. His outstanding knowledge of bioimpedance technology and ImpediMed’s IP have laid the foundation for its successful future. There will be no change to Greg’s current valuable consulting role as an executive reporting to CEO Rick Carreon.

“While we regret losing Greg from our Board, we are very pleased he will stay on as a consultant to the Company and grateful to him for his dedicated commitment to ImpediMed over many years. We thank him for his many contributions. Greg’s decision is largely due to his expanding role serving on additional boards; however we are confident that he will continue to add value to ImpediMed and more widely in the healthcare industry in coming years,” said Dr. Cherrell Hirst, Chairman of the Board.

In addition to Greg’s resignation from the Board, ImpediMed today announces the appointment and promotion of Morten Vigeland to Chief Financial Officer. Morten has been with ImpediMed since April 2011, and previously held the position of Vice President, Global Finance.

Morten has more than 15 years of experience in financial management in the medical technology industry. Previous roles include Chief Financial Officer of Access Scientific, Inc., a medical device company, where he completed multiple rounds of financing and corporate deals with C.R. Bard, Inc. and Teleflex, Inc. He was Corporate Controller for Venetec International, Inc. in its emerging growth period. Venetec was acquired by C.R. Bard, Inc. for $167 million in 2006, and Morten served as the Corporate Controller for C.R. Bard, Inc.’s StatLock Division post acquisition. His early experience was serving as Associate Director of Finance with Applied Molecular Evolution (AME), where he supported the IPO that raised more than $100 million. AME later merged with Eli Lilly & Co.

“Morten has an exceptional background in operations, finance and accounting, in startups and emerging growth businesses. His proven track record of strong financial management, execution, and strategy comes at a key time in the evolution of ImpediMed” said CEO Rick Carreon.

Morten holds an MBA from California State University, and a Bachelor of Science, Business Administration, Finance from the University of Colorado.

For further information contact:
Dr. Cherrell Hirst, ImpediMed Chairman T: +71(7)3860 3700 M: +61 411556124
Richard Carreon, ImpediMed CEO T: +1 (760) 585-2100

About ImpediMed
ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au